Buprenorphine alone or in combination with naloxone reduced the use of and craving for opiates addiction: COMMENTARY

Graham, Allan W.
May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p65
Academic Journal
Authors have provided impressive evidence supporting the safety, acceptability, and efficacy of buprenorphine in managing opioid dependence in an office setting. The study showed an 82% retention rate for the 4-week intervention period, despite requiring daily visits for patients to receive their medication. Patients who received buprenorphine had a 4-fold higher rate of drug-negative urine test results than those who received placebo. Despite these encouraging results, implementation of new buprenorphine therapies by primary care providers, or even addiction medicine physicians, will first require the removal of 5 substantial barriers.


Related Articles

  • Buprenorphine: a potential new treatment option for opioid dependence. Srivastava, Anita; Kahan, Meldon // CMAJ: Canadian Medical Association Journal;6/20/2006, Vol. 174 Issue 13, p1835 

    Presents research which discussed the use of buprenorphine as treatment for opioid dependence. Comparison between the efficacy of buprenorphine and methadone in treating patients that are dependent with opioid; Contributions of buprenorphine therapy to people experiencing opioid withdrawal...

  • Effect of Tramadol Use on Three Point-of-Care and One Instrument-Based Immunoassays for Urine Buprenorphine. Shaikh, Salima; Hull, Mindy J.; Bishop, Kenneth A.; Griggs, David A.; Long, William H.; Nixon, Andrea L.; Flood, James G. // Journal of Analytical Toxicology;Jun2008, Vol. 32 Issue 5, p339 

    The article investigates the impact of the popular analgesic Tramadol on three point-of-care (ACON, Quickstrip and ABMC) and an instrument-based (Cedia) urine buprenorphine immunoassays. Findings show that tramadol can cause false-positive urine buprenorphine results. Results also suggest that...

  • Buprenorphine Sublingual and Buccal (opioid dependence).  // AHFS Consumer Medication Information;Sep2016, p1 

    Buprenorphine (Subutex) and buprenorphine and naloxone (Suboxone) are used to treat opioid dependence (addiction to opioid drugs, including heroin and narcotic painkillers). Buprenorphine is in a class of medications called opioid partial agonist-antagonists, and naloxone is in a class of...

  • Assessment of the sedative effects of buprenorphine administered with 20 µg/kg detomidine in horses. Love, E. J.; Taylor, P. M.; Murrell, J.; Whay, H. R.; Waterman-Pearson, A. E. // Veterinary Record: Journal of the British Veterinary Association;4/16/2011, Vol. 168 Issue 15, p408 

    The aim of this randomised, observer-blinded, crossover study was to compare the effects of four treatments, administered intravenously to six horses: saline and saline; 10 µg/kg detomidine and 7.5 µg/kg buprenorphine; 20 µg/kg detomidine and 7.5 µg/kg buprenorphine; and 20 µg/kg...

  • Counseling Buprenorphine Patients: Information and Treatment Approaches for Counselors. McCann, Michael J. // Journal of Psychoactive Drugs;May2004 Supplement 2, Vol. 36, p139 

    The Drug Addiction Treatment Act of 2000 allows qualifying physicians to prescribe buprenorphine out of office-based practices to treat opioid-dependent patients, with the requirement that they have the ability to refer them to ancillary counseling services. It is likely that these patients will...

  • Benefits of Extended Duration Detoxification.  // Clinical Oncology Alert;Jan2009 Clinical Briefs, Vol. 14 Issue 1, p1 

    The article discusses research being done on extended versus short-term buprenorphine-naloxone for treatment of opioid-addicted youth. It references a study by G. E. Woody et al published in the 2008 issue of "JAMA." The study randomized opioid-addicted adults to either short-term buprenorphine...

  • RESEARCH BRIEFS: Single-injection addiction treatment.  // GP: General Practitioner;2/2/2004, p11 

    A sustained-release formulation of buprenorphine 58mg was given to five volunteer, physically dependent heroin abusers. It prevented withdrawal discomfort for six weeks and reduced the effects of opioid challenge injections without significant side-effects or the need for any additional medication.

  • A NEW APPROACH OF CONDUCTING RAPID TRANSFER TO BUPRENORPHINE AMONG ADDICTS WHO DID NOT FUNCTION EVEN ON EXTREMELY HIGH METHADONE DOSES. Sakoman, Slavko // Alcoholism: Journal on Alcoholism & Related Addictions;2008 Supplement 1, Vol. 44, p23 

    Since the initiation of methadone treatment of heroin addicts (1991), the number of heavy and complex cases of drug addicts that could not be stabilized using different approaches, including the usage of high daily doses of methadone, has significantly increased. Even in addicts with whom good...

  • Poor Man's Smack: A qualitative study of buprenorphine injecting in Melbourne, Australia. Horyniak, Danielle; Armstrong, Stuart; Higgs, Peter; Wain, David; Aitken, Campbell // Contemporary Drug Problems;Fall2007, Vol. 34 Issue 3, p525 

    Cross-sectional studies indicate that diversion and injection of buprenorphine intended for oral use is an emerging health issue for Victorian injecting drug users (IDUs). Between June and September 2006 we conducted in-depth interviews with 23 IDUs from Melbourne, Australia, exploring their...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics